4D Molecular Therapeutics CEO David Kirn disposes of USD 754,632 in common shares

• 4D Molecular Therapeutics President and CEO David Kirn sold 58,333 shares on Oct. 5, 2026.
• Sales priced at USD 12.9215 and USD 13.6104 per share.
• Kirn’s direct holding fell to 709,153 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-417068), on October 07, 2026, and is solely responsible for the information contained therein.